Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Forte Biosciences (FBRX) Non Operating Investment Income (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Non Operating Investment Income for 5 consecutive years, with -$10000.0 as the latest value for Q1 2020.

  • Quarterly Non Operating Investment Income fell 124.39% to -$10000.0 in Q1 2020 from the year-ago period, while the trailing twelve-month figure was -$18000.0 through Mar 2020, down 114.29% year-over-year, with the annual reading at $33000.0 for FY2019, 200.0% up from the prior year.
  • Non Operating Investment Income for Q1 2020 was -$10000.0 at Forte Biosciences, up from -$33000.0 in the prior quarter.
  • The five-year high for Non Operating Investment Income was $54000.0 in Q1 2016, with the low at -$74000.0 in Q1 2018.
  • Average Non Operating Investment Income over 5 years is $3866.7, with a median of -$1000.0 recorded in 2017.
  • Peak annual rise in Non Operating Investment Income hit 1000.0% in 2018, while the deepest fall reached 7300.0% in 2018.
  • Over 5 years, Non Operating Investment Income stood at -$9000.0 in 2016, then plummeted by 244.44% to -$31000.0 in 2017, then soared by 200.0% to $31000.0 in 2018, then plummeted by 206.45% to -$33000.0 in 2019, then surged by 69.7% to -$10000.0 in 2020.
  • According to Business Quant data, Non Operating Investment Income over the past three periods came in at -$10000.0, -$33000.0, and -$13000.0 for Q1 2020, Q4 2019, and Q3 2019 respectively.